Metastatic colorectal cancer patients
Conditions
Interventions
The test group will be asked to take the medical nutrition supplement twice per day, during the first 3 cycles of CAPOX-B treatment. The control group receives the same medical treatment with CAPOX-B
Sponsors
Nutricia Research B.V.
Uppsalalaan 12
3508 CT Utrecht, the Netherlands
Collaboration with University Medical Center Utrecht
Eligibility
Inclusion criteria
Inclusion criteria: 1. Histologically proven colorectal cancer 2. Presence of distant metastases 3. Eligible and scheduled for first line treatment with CAPOX-B systemic treatment 4. Performance status (WHO/ECOG) of 0 or 1 5. Age ¡Ý 18 years 6. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Presence of ileostoma or ileal pouch 2. Malnutrition Universal Screening Tool (MUST) score of ¡Ý2, indicating high risk of malnutrition 3. Body mass index < 20.0 kg/m2 4. Known intolerance or allergy to dairy, fish, or other ingredients of the test product 5. Known pregnancy or lactation 6. Current alcohol, drug or medication abuse in opinion of the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To explore the compliance to nutritional test product intake | — |
Secondary
| Measure | Time frame |
|---|---|
| - Tolerance and safety - Systemic treatment related parameters - Body weight and body composition - Quality of life and health status - Dietary intake - Physical activity - Fatigue - Blood chemistry | — |
Contacts
Public ContactEsmee Kolthof
Outcome results
None listed